Altering the viscoelastic properties of mucus-grown
Antibiotic resistance
Biofilm
Mucus
Pseudomonas aeruginosa
Respiratory infection
Viscoelasticity
Journal
Biofilm
ISSN: 2590-2075
Titre abrégé: Biofilm
Pays: Netherlands
ID NLM: 101764202
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
14
11
2022
revised:
15
01
2023
accepted:
19
01
2023
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
The viscoelastic properties of biofilms are correlated with their susceptibility to mechanical and chemical stress, and the airway environment in muco-obstructive pulmonary diseases (MOPD) facilitates robust biofilm formation. Hyperconcentrated, viscoelastic mucus promotes chronic inflammation and infection, resulting in increased mucin and DNA concentrations. The viscoelastic properties of biofilms are regulated by biopolymers, including polysaccharides and DNA, and influence responses to antibiotics and phagocytosis. We hypothesize that targeted modulation of biofilm rheology will compromise structural integrity and increase antibiotic susceptibility and mucociliary transport. We evaluate biofilm rheology on the macro, micro, and nano scale as a function of treatment with a reducing agent, a biopolymer, and/or tobramycin to define the relationship between the viscoelastic properties of biofilms and susceptibility. Disruption of the biofilm architecture is associated with altered macroscopic and microscopic moduli, rapid vector permeability, increased antibiotic susceptibility, and improved mucociliary transport, suggesting that biofilm modulating therapeutics will improve the treatment of chronic respiratory infections in MOPD.
Identifiants
pubmed: 36711323
doi: 10.1016/j.bioflm.2023.100104
pii: S2590-2075(23)00001-1
pmc: PMC9880403
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100104Informations de copyright
© 2023 The Authors. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Antimicrob Chemother. 2018 Oct 1;73(10):2762-2769
pubmed: 29982453
ACS Infect Dis. 2020 Jul 10;6(7):1940-1950
pubmed: 32510928
Am J Physiol Lung Cell Mol Physiol. 2019 Oct 1;317(4):L498-L509
pubmed: 31389736
Biophys J. 2020 May 19;118(10):2354-2365
pubmed: 32304636
Biophys J. 2001 Oct;81(4):1930-7
pubmed: 11566767
Hum Exp Toxicol. 2019 Jun;38(6):724-733
pubmed: 30935230
J Vis Exp. 2012 Jun 05;(64):e3857
pubmed: 22711026
N Engl J Med. 2019 May 16;380(20):1941-1953
pubmed: 31091375
J Clin Invest. 2019 Oct 1;129(10):4089-4090
pubmed: 31524633
J Vis Exp. 2015 Dec 04;(106):e53093
pubmed: 26709625
Adv Drug Deliv Rev. 2009 Feb 27;61(2):86-100
pubmed: 19166889
PLoS One. 2014 Feb 18;9(2):e87681
pubmed: 24558372
J Cyst Fibros. 2022 Nov;21(6):959-966
pubmed: 35437233
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18131-6
pubmed: 17116883
Pathog Dis. 2014 Apr;70(3):212-8
pubmed: 24376149
Pediatr Pulmonol. 1995 Aug;20(2):63-70
pubmed: 8570304
Am J Respir Crit Care Med. 2020 Mar 15;201(6):661-670
pubmed: 31765597
PLoS One. 2010 Dec 14;5(12):e15668
pubmed: 21179489
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):848-52
pubmed: 23271809
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30745390
Am J Respir Cell Mol Biol. 2022 Aug;67(2):253-265
pubmed: 35486871
Biofouling. 2011 Feb;27(2):207-15
pubmed: 21279860
Antimicrob Agents Chemother. 2009 Mar;53(3):1204-9
pubmed: 19064900
Soft Matter. 2011;7(7):3307-3314
pubmed: 21760831
J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):378-85
pubmed: 26741301
ACS Biomater Sci Eng. 2017;3(6):1017-1026
pubmed: 30320206
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1482-7
pubmed: 17244708
Eur Respir J. 2018 Dec 6;52(6):
pubmed: 30361244
Biomacromolecules. 2017 Nov 13;18(11):3654-3664
pubmed: 28903557
FEMS Microbiol Rev. 2015 Mar;39(2):234-45
pubmed: 25725015
Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2121731119
pubmed: 35324331
mSphere. 2022 Aug 31;7(4):e0029122
pubmed: 35968965
Biomacromolecules. 2016 Apr 11;17(4):1536-42
pubmed: 26957140
Biophys J. 2021 Apr 20;120(8):1387-1395
pubmed: 33705757
Appl Environ Microbiol. 2010 Sep;76(17):5860-9
pubmed: 20639359
Appl Environ Microbiol. 1994 Aug;60(8):2711-6
pubmed: 16349345
Nat Commun. 2021 Jan 11;12(1):249
pubmed: 33431872
Am J Physiol Lung Cell Mol Physiol. 2015 Jul 15;309(2):L99-108
pubmed: 25979076
Biofouling. 2015;31(9-10):775-87
pubmed: 26610146
Sci Rep. 2018 Jun 26;8(1):9691
pubmed: 29946126
Adv Drug Deliv Rev. 2018 Jan 15;124:64-81
pubmed: 29246855
Antimicrob Agents Chemother. 2005 Jun;49(6):2467-73
pubmed: 15917548
J Infect Dis. 2000 Mar;181(3):1180-4
pubmed: 10720551
Biofouling. 2012;28(2):187-98
pubmed: 22352315
Physiol Rev. 2022 Oct 1;102(4):1757-1836
pubmed: 35001665
Biofouling. 2013;29(4):413-21
pubmed: 23574333
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944166
Trends Microbiol. 2020 Aug;28(8):668-681
pubmed: 32663461
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2620-6
pubmed: 26833153
J Mater Chem B. 2020 May 28;8(20):4395-4401
pubmed: 32400814
J Wound Care. 2018 May 2;27(5):273-277
pubmed: 29738295
Antimicrob Agents Chemother. 2015 Oct;59(10):6506-13
pubmed: 26239983
NPJ Biofilms Microbiomes. 2018 Jun 29;4:13
pubmed: 29977590
NPJ Biofilms Microbiomes. 2017 Jan 23;3:1
pubmed: 28649402
J Bacteriol. 2007 Nov;189(22):7945-7
pubmed: 17675377